UPCC 09317: A Phase 1b/2a Multi-Center Open-Label Study to Evaluate the Safety and Efficacy of Combination Treatment with MEDI0457 (INO-3112) and Durvalumab (MEDI4736) in Patients with Recurrent/Metastatic Human Papilloma Virus Associated Head and Neck Squamous Cancer

UPCC 09317: A Phase 1b/2a Multi-Center Open-Label Study to Evaluate the Safety and Efficacy of Combination Treatment with MEDI0457 (INO-3112) and Durvalumab (MEDI4736) in Patients with Recurrent/Metastatic Human Papilloma Virus Associated Head and Neck Squamous Cancer
99 years or below
All
Phase 2
1 Location

Brief description of study

The main purpose of this study is to measure how well and how safe MEDI0457 vaccine in combination with Durvalumab is in treating patients with recurrent/metastatic human papilloma virus associated head and neck squamous cancer.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: TBD, tbd, tbd
  • Age: 99 years or below
  • Gender: All
Updated on 27 Aug 2018. Study ID: 827182

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.